Materials
Presentations
Welcome from the Forum
Mitchell Leus, Forum for Collaborative Research
Introductory Remarks: HBV Forum Chairs
Veronica Miller, Forum for Collaborative Research
Marion Peters, Northwestern University
Oliver Lenz, Janssen Pharmaceuticals
Session I: Working Group Updates
Stopping Finite Treatment Manuscript
Marion Peters, Northwestern University
Advocate Perspective on Finite Treatment
Chari Cohen, Hepatitis B Foundation
Jessica Hicks, World Hepatitis Alliance
HDV RNA Assays Manuscript
Norah Terrault, University of Southern California
Heiner Wedemeyer, Hannover Medical School
Advocate Perspective on HDV Therapeutic Development
Chari Cohen, Hepatitis B Foundation
Jessica Hicks, World Hepatitis Alliance
Session II: MAPPED (Mechanisms of Action and Patient Populations: Emphasizing Diversity) Working Group
MAPPED Working Group
Jordan Feld, Toronto Centre for Liver Disease
Michael Biermer, Janssen Pharmaceuticals
Panel Discussion – MAPPED Working Group
Chari Cohen, Hepatitis B Foundation
Sue Currie, Virion Therapeutics
Grace Dolman, GlaxoSmithKline
Jessica Hicks, World Hepatitis Alliance
Carey Hwang, Vir Biotechnology
Pietro Lampertico, University of Milan
Jean-Michel Pawlotsky, University of Paris-Est
Session III: Challenges in PD-1 and PD-L1 Therapies
Overview on Challenges in PD-1 & PD-L1 HBV Trials
Adam Gehring, ICE-HBV, Toronto Centre for Liver Disease
Session IV: Current and Future Landscape of HBV Biomarkers
Biomarkers Working Group
Mitchell Leus, Forum for Collaborative Research
Session V: Frontiers in HBV Drug Development
Overview on Long-Acting HBV Treatments
David Thomas, Johns Hopkins University
Patient Perspective on Long-Acting HBV Treatments
Danjuma Adda, World Hepatitis Alliance
Su Wang, Center for Asian Health, Saint Barnabas Medical Center
Thomas Tu, Westmead Institute for Medical Research, Hepatitis B Voices Australia, HepBCommunity.org
FDA Perspective on Long-Acting HBV Treatments
Poonam Mishra, U.S. Food and Drug Administration
Jonathan Rawson, U.S. Food and Drug Administration
EMA Perspective on Long-Acting HBV Treatments
Stephanie Buchholz, European Medicines Agency
